Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms

Insulin resistance is common in individuals with obesity or type 2 diabetes (T2D), in which circulating insulin levels are frequently increased. Recent epidemiological and clinical evidence points to a link between insulin resistance and cancer. The mechanisms for this association are unknown, but hyperinsulinaemia (a hallmark of insulin resistance) and the increase in bioavailable insulin-like growth factor I (IGF-I) appear to have a role in tumor initiation and progression in insulin-resistant patients. Insulin and IGF-I inhibit the hepatic synthesis of sex-hormone binding globulin (SHBG), whereas both hormones stimulate the ovarian synthesis of sex steroids, whose effects, in breast epithelium and endometrium, can promote cellular proliferation and inhibit apoptosis. Furthermore, an increased risk of cancer among insulin-resistant patients can be due to overproduction of reactive oxygen species (ROS) that can damage DNA contributing to mutagenesis and carcinogenesis. On the other hand, it is possible that the abundance of inflammatory cells in adipose tissue of obese and diabetic patients may promote systemic inflammation which can result in a protumorigenic environment. Here, we summarize recent progress on insulin resistance and cancer, focusing on various implicated mechanisms that have been described recently, and discuss how these mechanisms may contribute to cancer initiation and progression.

[1]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[2]  A. Costantino,et al.  Insulin Receptor Isoform A, a Newly Recognized, High-Affinity Insulin-Like Growth Factor II Receptor in Fetal and Cancer Cells , 1999, Molecular and Cellular Biology.

[3]  R. Reeves,et al.  High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. , 1996, Progress in nucleic acid research and molecular biology.

[4]  R. Kitazawa,et al.  MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. , 2006, The Journal of clinical investigation.

[5]  D. Lin,et al.  Fen1 mutations result in autoimmunity, chronic inflammation and cancers , 2007, Nature Medicine.

[6]  H. Grosse.  [Diabetes and cancer]. , 1956, Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten.

[7]  G. Z. Rocha,et al.  Epidemiological and molecular mechanisms aspects linking obesity and cancer. , 2009, Arquivos brasileiros de endocrinologia e metabologia.

[8]  R. Schiel,et al.  Diabetes, insulin, and risk of cancer. , 2006, Methods and findings in experimental and clinical pharmacology.

[9]  A. Brunetti,et al.  A Nucleoprotein Complex Containing Sp1, C/EBPβ, and HMGI-Y Controls Human Insulin Receptor Gene Transcription , 2003, Molecular and Cellular Biology.

[10]  R. Hardy,et al.  The metabolic syndrome: A high-risk state for cancer? , 2006, The American journal of pathology.

[11]  J. Selby,et al.  Genetic and environmental influences on insulin levels and the insulin resistance syndrome: an analysis of women twins. , 1996, American journal of epidemiology.

[12]  Puneeth Iyengar,et al.  Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization , 2003, Oncogene.

[13]  J. Blenis,et al.  MAPK signal specificity: the right place at the right time. , 2006, Trends in biochemical sciences.

[14]  J. Stockman.  Functional Variants of the HMGA1 Gene and Type 2 Diabetes Mellitus , 2012 .

[15]  C. Madeddu,et al.  Obesity, Inflammation, and Postmenopausal Breast Cancer: Therapeutic Implications , 2011, TheScientificWorldJournal.

[16]  M. Woodward,et al.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies , 2005, British Journal of Cancer.

[17]  Qiwen Ben,et al.  Risk of esophageal cancer in diabetes mellitus: a meta-analysis of observational studies , 2011, Cancer Causes & Control.

[18]  S. Singh,et al.  Differential expression and signaling activation of insulin receptor isoforms A and B: A link between breast cancer and diabetes , 2011, Growth factors.

[19]  D. Sabatini,et al.  Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.

[20]  C. Yip,et al.  Mechanism of transmembrane signaling: insulin binding and the insulin receptor. , 2000, Biochemistry.

[21]  D. Saur,et al.  HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells. , 2007, Cancer research.

[22]  Chenguang Wang,et al.  Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution , 2010, Cell cycle.

[23]  Jun Liu,et al.  Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. , 2011, European journal of cancer.

[24]  B. Spiegelman,et al.  IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[25]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[26]  D. Rose,et al.  Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. , 2007, Endocrine-related cancer.

[27]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[28]  R. Busse,et al.  From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. , 2004, Diabetes.

[29]  F. Sotgia,et al.  HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells , 2010, Cell cycle.

[30]  C. Kahn,et al.  From mice to men: insights into the insulin resistance syndromes. , 2006, Annual review of physiology.

[31]  H. Masoudi,et al.  Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. , 2008, Cancer research.

[32]  E. Ding,et al.  Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. , 2009, JAMA.

[33]  M. Zou,et al.  Molecular basis of thyroid cancer. , 1994, Endocrine reviews.

[34]  B. Spiegelman,et al.  Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.

[35]  F. Frasca,et al.  The role of insulin receptors and IGF-I receptors in cancer and other diseases. , 2008, Archives of physiology and biochemistry.

[36]  C Collins,et al.  Insulin‐like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. , 1986, The EMBO journal.

[37]  C. Chao,et al.  Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: a systematic review and meta-analysis. , 2008, American journal of epidemiology.

[38]  R. Baserga,et al.  Control of cell size through phosphorylation of upstream binding factor 1 by nuclear phosphatidylinositol 3-kinase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  K. Clément,et al.  Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. , 2012, Journal of hepatology.

[40]  G. Reaven,et al.  A Comparison of the Relative Effects of Obesity and Non-insulin-dependent Diabetes Mellitus on In Vivo Insulin-stimulated Glucose Utilization , 1984, Diabetes.

[41]  Xian-gui Hu,et al.  Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis , 2012, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[42]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[43]  R. Reeves,et al.  HMGI/Y proteins: flexible regulators of transcription and chromatin structure. , 2001, Biochimica et biophysica acta.

[44]  M. Brownlee,et al.  Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. , 1994, The Journal of clinical investigation.

[45]  M. Karin,et al.  Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Alicja Wolk,et al.  Diabetes mellitus and risk of breast cancer: A meta‐analysis , 2007, International journal of cancer.

[47]  S. Larsson,et al.  Diabetes mellitus and risk of bladder cancer: a meta-analysis , 2006, Diabetologia.

[48]  J. B. Carvalheira,et al.  Vias de Sinalização da Insulina , 2002 .

[49]  Y. Ebina,et al.  Characterization of the promoter region of the human insulin receptor gene. Evidence for promoter activity. , 1987, The Journal of biological chemistry.

[50]  J. Pessin,et al.  Insulin regulation of the Ras activation/inactivation cycle , 1998, Molecular and Cellular Biochemistry.

[51]  D. Clemmons,et al.  Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer , 2007, Nature Reviews Drug Discovery.

[52]  J. Blenis,et al.  ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions , 2004, Microbiology and Molecular Biology Reviews.

[53]  C. Kahn,et al.  The insulin signaling system. , 1994, The Journal of biological chemistry.

[54]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[55]  A. Brunet,et al.  Nuclear translocation of p42/p44 mitogen‐activated protein kinase is required for growth factor‐induced gene expression and cell cycle entry , 1999, The EMBO journal.

[56]  A. Brunetti,et al.  Identification of unique nuclear regulatory proteins for the insulin receptor gene, which appear during myocyte and adipocyte differentiation. , 1993, The Journal of clinical investigation.

[57]  D. Corley,et al.  Is Diabetes Mellitus an Independent Risk Factor for Colon Cancer and Rectal Cancer? , 2011, The American Journal of Gastroenterology.

[58]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[59]  C. Ersoy,et al.  Relation between insulin resistance and serum concentrations of IL-6 and TNF-alpha in overweight or obese women with early stage breast cancer. , 2005, Cytokine.

[60]  S. Seino,et al.  Structure of the human insulin receptor gene and characterization of its promoter. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[61]  G. Steinberg,et al.  Adipose tissue as an endocrine organ , 2010, Molecular and Cellular Endocrinology.

[62]  R. DeFronzo,et al.  Hepatic and peripheral insulin resistance: A common feature of Type 2 (non-insulin-dependent) and Type 1 (insulin-dependent) diabetes mellitus , 1982, Diabetologia.

[63]  A. Brunetti,et al.  Regulating Insulin-Receptor-Gene Expression by Differentiation and Hormones , 1990, Diabetes Care.

[64]  A. Brunetti,et al.  Transcriptional regulation of human insulin receptor gene by the high‐mobility group protein HMGI(Y) , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[65]  T. Unterman,et al.  FoxO proteins in insulin action and metabolism , 2005, Trends in Endocrinology & Metabolism.

[66]  H. El‐Serag,et al.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[67]  D. Straus.  Nutritional regulation of hormones and growth factors that control mammalian growth , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  M. Stampfer,et al.  Insulin receptor expression and function in human breast cancer cell lines. , 1992, Cancer research.

[69]  D. Clemmons,et al.  Nutritional regulation of IGF-I and IGF binding proteins. , 1991, Annual review of nutrition.

[70]  Qiwen Ben,et al.  Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta‐analysis of cohort studies , 2012, International journal of cancer.

[71]  Yan-Qing Li,et al.  Diabetes mellitus and increased risk of biliary tract cancer: systematic review and meta-analysis , 2011, Cancer Causes & Control.

[72]  P. Goss,et al.  The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. , 2008, The oncologist.

[73]  A. Fusco,et al.  Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer. , 2006, Cancer research.

[74]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[75]  S. Larsson,et al.  Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies , 2011, Diabetologia.

[76]  E. Giovannucci,et al.  The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. , 2007, Gastroenterology.

[77]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[78]  C. Mantzoros,et al.  Diabetes mellitus and risk of endometrial cancer: a meta-analysis , 2007, Diabetologia.

[79]  C. Osborne,et al.  Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[80]  C. Kahn.  The Gordon Wilson Lecture. Lessons about the control of glucose homeostasis and the pathogenesis of diabetes from knockout mice. , 2003, Transactions of the American Clinical and Climatological Association.

[81]  José Luis de la Pompa,et al.  Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.

[82]  Kahn Cr.  The Gordon Wilson Lecture. Lessons about the control of glucose homeostasis and the pathogenesis of diabetes from knockout mice. , 2003 .

[83]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[84]  G. Fantuzzi.  Adipose tissue, adipokines, and inflammation. , 2005, The Journal of allergy and clinical immunology.

[85]  Michael T. Lotze,et al.  Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.

[86]  B. Howard,et al.  Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. , 2003, Diabetes care.

[87]  J. Ketelslegers,et al.  Nutritional regulation of the insulin-like growth factors. , 1994, Endocrine reviews.

[88]  M. Pignatelli,et al.  Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor γ in the MCF-7 breast cancer cell line , 2003, Oncogene.

[89]  R. Brand,et al.  Elevated insulin receptor content in human breast cancer. , 1990, The Journal of clinical investigation.

[90]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[91]  F. Sotgia,et al.  Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? , 2011, BMC medicine.

[92]  Simeon I. Taylor,et al.  Deconstructing Type 2 Diabetes , 1999, Cell.

[93]  R. Kaaks,et al.  Energy balance and cancer: the role of insulin and insulin-like growth factor-I , 2001, The Proceedings of the Nutrition Society.

[94]  C Bogardus,et al.  Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. , 2001, Obesity research.

[95]  N. Berger,et al.  Energy balance, host-related factors, and cancer progression. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  Robert H. Bell,et al.  Insulin receptor expression by human prostate cancers , 2009, The Prostate.

[97]  Manal M. Hassan,et al.  Diabetes and risk of pancreatic cancer: a pooled analysis of three large case–control studies , 2011, Cancer Causes & Control.

[98]  P. H. Seeburg,et al.  Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes , 1985, Nature.

[99]  Edward Giovannucci,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[100]  Morihiro Matsuda,et al.  Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.

[101]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[102]  S. Larsson,et al.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[103]  Chiun Hsu,et al.  Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis , 2008, Breast Cancer Research.

[104]  I. Goldfine.  The insulin receptor: molecular biology and transmembrane signaling. , 1987, Endocrine reviews.

[105]  Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[106]  Robert L Hanson,et al.  Components of the "metabolic syndrome" and incidence of type 2 diabetes. , 2002, Diabetes.

[107]  C. Conover,et al.  Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. , 2002, Endocrinology.

[108]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[109]  R. Unger.  Reinventing type 2 diabetes: pathogenesis, treatment, and prevention. , 2008, JAMA.

[110]  M. Murphy,et al.  Geometry, kinematics, and landscape characteristics of an active transtension zone, Karakoram fault system, Southwest Tibet , 2006 .

[111]  C. Lamendola,et al.  Insulin Resistance Syndrome , 2004, The Journal of cardiovascular nursing.

[112]  Herbert Tilg,et al.  Adipocytokines: mediators linking adipose tissue, inflammation and immunity , 2006, Nature Reviews Immunology.

[113]  J. Mitri,et al.  Diabetes and Risk of Non-Hodgkin's Lymphoma , 2008, Diabetes Care.

[114]  R. Parsons,et al.  PTEN: life as a tumor suppressor. , 2001, Experimental cell research.

[115]  J. Wallace,et al.  The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[116]  O. Rosen.  Structure and Function of Insulin Receptors , 1989, Diabetes.

[117]  C. Croce,et al.  Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice , 2005, Nature Medicine.

[118]  G. Franzoso,et al.  Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance , 2006, Oncogene.

[119]  B. Spiegelman,et al.  Molecular mechanisms of cancer development in obesity , 2011, Nature Reviews Cancer.

[120]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[121]  A. Brunetti,et al.  New Target Genes for the Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Antitumour Activity: Perspectives from the Insulin Receptor , 2009, PPAR research.

[122]  A. Ullrich,et al.  Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. , 1990, The Biochemical journal.

[123]  C. Osborne,et al.  Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. , 1978, Cancer research.

[124]  J. Schölmerich,et al.  Mechanisms of Disease: adipokines and breast cancer—endocrine and paracrine mechanisms that connect adiposity and breast cancer , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[125]  H. Klocker,et al.  Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer , 2010, British Journal of Cancer.